Status:
UNKNOWN
Changes in the Prevalence of Oncogenic HPV Types
Lead Sponsor:
Kanazawa Medical University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Papillomavirus Vaccines
Papillomavirus Infections
Eligibility:
FEMALE
16-39 years
Brief Summary
In Japan, nationwide prophylactic HPV vaccination was implemented in 2010; a bivalent vaccine was given from 2010 to 2012, and a quadrivalent vaccine from 2012. However, the program essentially ceased...
Detailed Description
Recently, HPV prevalence has decreased dramatically in the USA (Markowitz LE, Pediatrics, 2019). Surprisingly, the nonavalent vaccine optimally decreased the prevalence of the most common, high-risk H...
Eligibility Criteria
Inclusion
- Japanese women who seek cervical cancer screening or gynecological consultations
- Women with benign conditions
- 16-39 year-old
- Women must be sexually experienced, as defined by sexual contact (oral-genital or genital-genital) with at least one male or female partner.
Exclusion
- Women with STDs
- Women with premalignant lesions of the cervicovaginal tract
- Women suffering from any cancer
- Women with any severe acute or chronic disease, and/or psychological problems
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2022
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04671823
Start Date
December 1 2020
End Date
March 31 2022
Last Update
December 23 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.